Elite Pharma reports positive bioequivalence study for undisclosed anticoagulant generic; brand sales $27B

ELITE PHARMACEUTICALS INC /NV/

Positive pivotal bioequivalence results for an undisclosed generic anticoagulant; product is bioequivalent to brand.
Branded product sales $27B (12 months ending April 2025); no generic marketed; unexpired Orange Book patent exists.
Elite will compile data to file ANDA with FDA; commercialization conditional on FDA approval and patent resolution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.